• Osteoblast ECM1 Drives Enzalutamide Resistance in Bone PCa

  2026-09-24

  The study identifies osteoblast-derived ECM1 as a bone-microenvironment signal that can promote enzalutamide resistance in prostate cancer cells. It links ECM1 engagement of cell-surface ENO1 to ENO1 Y189 phosphorylation, GRB2/SOS1 recruitment, and MAPK activation, and reports that targeting ECM1 or ENO1 can restore drug sensitivity in the models studied.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-09-24

  The study reports that three inhibitors can both block p38α MAP kinase activity and increase removal of its activation-loop phosphate by the phosphatase WIP1. Structural data suggest that inhibitor binding exposes the phospho-threonine, offering a conformational mechanism for kinase deactivation and a design concept that merits further testing.

• TMAO Activates PERK in Zebrafish NAFLD Progression

  2026-09-23

  A 2024 study reports that dietary trimethylamine N-oxide (TMAO) can induce liver steatosis, inflammation, injury, and fibrosis in zebrafish, with PERK signaling activated in animal and cell models. The findings connect a gut microbiota-related metabolite to liver pathology and provide a framework for testing whether PERK activity contributes causally to disease progression.

• SCH772984: ERK1/2 Inhibitor Workflow

  2026-09-23

  SCH772984 enables selective, ATP-competitive ERK1/2 inhibition for pathway validation, resistance modeling, and combination studies with radiation or ferroptosis-focused assays. Its nanomolar biochemical potency and compatibility with phospho-protein, viability, colony-formation, and xenograft workflows make it useful for connecting MAPK signaling to tumor phenotypes.

• GDC-0994: Selective ERK1/2 Inhibitor

  2026-09-22

  GDC-0994 is a potent, selective ERK1/2 inhibitor for studying MAP kinase signaling in cancer and cholestasis models. Its reported activity against ERK1 and ERK2, combined with preclinical xenograft and zebrafish findings, supports pathway-focused research rather than clinical use.

• tFUS Regulates SHP2 to Limit Stroke Neuroinflammation

  2026-09-22

  This 2025 study identifies the Nespas/miR-383-3p/SHP2 axis as a mechanistic link between low-intensity transcranial focused ultrasound stimulation and reduced NLRP3-related neuroinflammation after ischemic stroke. Its combination of a transient MCAO rat model, microglial OGD/R experiments, RNA sequencing, and targeted molecular perturbation provides a useful framework for studying SHP2-dependent neuroprotection.

• Recombinant Human EGF for 3D Spheroid Assays

  2026-09-21

  Use recombinant human EGF to introduce a controlled EGFR-linked variable into 3D glioblastoma spheroid workflows. This guide combines a streamlined 96-well stemness assay with practical dosing, handling, troubleshooting, and orthogonal validation strategies.

• IPR-803: From uPAR Binding to Metastasis Insight

  2026-09-21

  IPR-803 is a urokinase receptor inhibitor for connecting uPAR–uPA target engagement with invasion, angiogenesis, and metastasis phenotypes. This evidence-centered guide explains how to interpret its biochemical, cellular, and animal data without confusing anti-invasion activity with general cytotoxicity.

• SD 169: p38 MAPK Workflow and Applications

  2026-09-20

  SD 169 (indole-5-carboxamide) gives researchers a practical way to interrogate p38α/β signaling in inflammation, apoptosis, type 1 diabetes, and nerve repair models. This guide connects dose-controlled pathway inhibition with phosphatase-aware assays, troubleshooting, and translationally relevant readouts.

• EGF-Driven Migration Without EMT in A549 Cells

  2026-09-19

  Schelch et al. showed that Epidermal Growth Factor (EGF) stimulates migration in A549 lung adenocarcinoma cells without inducing the epithelial–mesenchymal transition (EMT) or increasing invasion. The study separates migration from invasive behavior and identifies MAPK dependence as a distinguishing feature of EGF-driven movement, with implications for interpreting cancer-cell motility assays.

• SB203580 and the FAK–p38–GATA4 Repair Axis

  2026-09-18

  SB203580 is a selective p38 MAPK inhibitor with unusual value for testing pathway dependence in regenerative biology. This article connects its pharmacology to the FAK–p38–GATA4 axis identified in diabetic bladder dysfunction research and translates that insight into better assay decisions.

• Clozapine Workflows for Schizophrenia Research

  2026-09-18

  Clozapine provides a pharmacological benchmark for receptor biology, ERK1/2 signaling activation, and treatment-resistant schizophrenia models. This guide pairs practical dosing and assay workflows with the reference study’s region-specific magnetic stimulation strategy to improve mechanistic resolution and reproducibility.

• IPR-803: Urokinase Receptor Inhibitor Workflows

  2026-09-17

  IPR-803 is a mechanistic small-molecule uPAR–uPA interaction blocker for separating tumor invasion and angiogenesis from general cytotoxicity. This guide translates its biochemical, breast cancer, pancreatic cancer, and formulation-linked evidence into practical assay workflows and troubleshooting decisions.

• Sildenafil Citrate: PDE5 Research Workflows

  2026-09-17

  Build reproducible cGMP, vascular, PASMC, and proteoform-aware experiments around Sildenafil Citrate. This guide connects biochemical potency with ERK1/ERK2 phosphorylation modulation, vascular smooth muscle relaxation, and native-membrane off-target analysis.

• pH-Responsive i-Motif ASO Prodrugs in MYCN Cells

  2026-09-16

  This study developed hairpin antisense oligonucleotide prodrugs that use an i-motif as an acid-responsive structural switch. Systematic variation of loop and stem architecture identified R3-5 and R5-5 as promising constructs for MYCN silencing and apoptosis induction in SK-BE(2) cells, while also defining important stability and release trade-offs.

8076 records 1/539 page Next 12345 下5页 Last page